[go: up one dir, main page]

PE20040554A1 - Vacunas que comprenden proteinas de fusion - Google Patents

Vacunas que comprenden proteinas de fusion

Info

Publication number
PE20040554A1
PE20040554A1 PE2003000573A PE2003000573A PE20040554A1 PE 20040554 A1 PE20040554 A1 PE 20040554A1 PE 2003000573 A PE2003000573 A PE 2003000573A PE 2003000573 A PE2003000573 A PE 2003000573A PE 20040554 A1 PE20040554 A1 PE 20040554A1
Authority
PE
Peru
Prior art keywords
couples
fusion
fusion proteins
antigens
refers
Prior art date
Application number
PE2003000573A
Other languages
English (en)
Inventor
Silva Teresa Elisa Virginia Cabezon
Jonathan H Ellis
Catherine Marie Ghislaine Gerard
Paul A Hamblin
Y De Bassols Carlota Vinals
Remi Palmantier
Original Assignee
Glaxosmithkline Biolog Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0213365.0A external-priority patent/GB0213365D0/en
Priority claimed from GB0300914A external-priority patent/GB0300914D0/en
Application filed by Glaxosmithkline Biolog Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biolog Sa
Publication of PE20040554A1 publication Critical patent/PE20040554A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A PAREJAS DE FUSION QUE ACTUAN COMO PAREJAS DE FUSION INMUNOLOGICAS Y COMPRENDE: A) UN DOMINIO DE UNION A COLINA DERIVADO DEL EXTREMO C DE LytA, LA SEC ID N° 8, O UNA SECUENCIA DE POLIPEPTIDOS CON AL MENOS 85% DE IDENTIDAD; B) UN EPITOPO AUXILIAR T PROMISCUO; C) COMPRENDE ADEMAS UNA PROTEINA HETEROLOGA DERIVADA DE UN ORGANISMO SELECCIONADO DEL VIRUS VIH-1, HERPEX SIMPLE HUMANO, CITOMEGALOVIRUS, ROTAVIRUS, ENTRE OTROS, QUE SE CONJUGA QUIMICAMENTE CON DICHA PAREJA DE FUSION. SE REFIERE TAMBIEN A SU FABRICACION Y EMPLEO COMO VACUNAS. DICHAS PAREJAS SON UTILES EN CONSTRUCCIONES QUE COMPRENDEN AUTOANTIGENOS. POR EJEMPLO, ANTIGENOS DE TUMORES ESPECIFICOS O DE TEJIDOS ESPECIFICOS
PE2003000573A 2002-06-11 2003-06-09 Vacunas que comprenden proteinas de fusion PE20040554A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0213365.0A GB0213365D0 (en) 2002-06-11 2002-06-11 Novel compounds
GB0300914A GB0300914D0 (en) 2003-01-15 2003-01-15 Vaccines

Publications (1)

Publication Number Publication Date
PE20040554A1 true PE20040554A1 (es) 2004-09-30

Family

ID=29738082

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000573A PE20040554A1 (es) 2002-06-11 2003-06-09 Vacunas que comprenden proteinas de fusion

Country Status (27)

Country Link
US (1) US20060147477A1 (es)
EP (1) EP1511768B1 (es)
JP (1) JP2006512047A (es)
KR (1) KR20050010040A (es)
CN (1) CN100360558C (es)
AR (1) AR040178A1 (es)
AT (1) ATE359295T1 (es)
AU (1) AU2003246411A1 (es)
BR (1) BR0311732A (es)
CA (1) CA2487831A1 (es)
CO (1) CO5631450A2 (es)
DE (1) DE60313163T2 (es)
DK (1) DK1511768T3 (es)
ES (1) ES2285174T3 (es)
IL (1) IL165372A0 (es)
IS (1) IS7547A (es)
MX (1) MXPA04012443A (es)
MY (1) MY139557A (es)
NO (1) NO20045148L (es)
NZ (1) NZ537125A (es)
PE (1) PE20040554A1 (es)
PL (1) PL374534A1 (es)
PT (1) PT1511768E (es)
RU (1) RU2004135541A (es)
TW (1) TW200400970A (es)
UY (1) UY27840A1 (es)
WO (1) WO2003104272A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
ATE491467T1 (de) * 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
US8501198B2 (en) * 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
GB0417494D0 (en) * 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
AU2006209246A1 (en) * 2005-01-28 2006-08-03 Biomodifying Llc Anti-MUC1 alpha/beta antibodies
AU2007211104A1 (en) * 2006-01-27 2007-08-09 University Of Mississippi Medical Center Thermally-targeted delivery of medicaments, including doxorubicin
EP2392673A1 (en) 2006-06-02 2011-12-07 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the FOXP3 gene
CN101553252A (zh) * 2006-12-06 2009-10-07 诺华有限公司 包含来自于四株流感病毒的抗原的疫苗
ES2321788B1 (es) * 2007-01-29 2010-03-11 Universidad Miguel Hernandez Dominios proteicos de afinidad a colina para mejorar la expresion, inmovilizacion y purificacion de polipetidos.
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
ES2546213T3 (es) 2008-03-03 2015-09-21 Novartis Ag Compuestos y composiciones como moduladores de la actividad de TLR
WO2009114202A2 (en) * 2008-03-14 2009-09-17 The United States Of America As Represented By The Secretary Of The Navy Vaccine and immunization method using plasmodium antigen 2
WO2010036293A1 (en) * 2008-09-24 2010-04-01 The Johns Hokins University Malaria vaccine
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
PL2396032T3 (pl) 2009-02-10 2017-05-31 Seqirus UK Limited Szczepionki przeciw grypie o obniżonych zawartościach skwalenu
US20110229514A1 (en) * 2009-03-16 2011-09-22 Denise Doolan Vaccine and immunization method using plasmodium antigen 2
CN102438649A (zh) 2009-03-24 2012-05-02 诺华有限公司 脑膜炎球菌h因子结合蛋白和肺炎球菌结合糖的组合物
CN102762226A (zh) 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
EP2475385A1 (en) 2009-09-10 2012-07-18 Novartis AG Combination vaccines against respiratory tract diseases
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
WO2011084549A1 (en) 2009-12-15 2011-07-14 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
CA2786969C (en) * 2010-01-27 2018-07-24 Glaxosmithkline Biologicals S.A. Modified tuberculosis antigens
EP2549990A1 (en) 2010-03-23 2013-01-30 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
PL2598165T3 (pl) 2010-07-26 2018-02-28 Qu Biologics Inc. Immunogenne kompozycje przeciwzapalne
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
EP2744918A4 (en) 2011-08-17 2015-06-10 Globeimmune Inc IMMUNOTHERAPEUTIC YEAST MUC1 COMPOSITIONS AND USES THEREOF
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US9827190B2 (en) 2013-02-01 2017-11-28 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists
RU2598265C2 (ru) * 2013-07-26 2016-09-20 Амир Закиевич Максютов Полиэпитопные иммуногенные полипептиды и способы их применения
RU2724895C2 (ru) 2014-05-02 2020-06-26 Кью Байолоджикс Инк. Противомикробная иммуномодуляция
CN108164586B (zh) * 2018-01-22 2021-03-26 西南医科大学 合成多肽及其应用
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
FR3100819B1 (fr) * 2019-09-18 2024-04-19 Centre Nat Rech Scient Production et fonctionnalisation de nanoparticules dérivées du phage T5 et utilisations thérapeutiques
CN110922455B (zh) * 2019-12-28 2023-01-13 重庆艾力彼生物科技有限公司 铜绿假单胞菌疫苗重组蛋白rePilA-FliC及制备方法和应用
KR20230098825A (ko) 2020-11-04 2023-07-04 엘리고 바이오사이언스 씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자
CN113278078B (zh) * 2021-05-25 2023-03-21 西南医科大学 多肽序列及其应用
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用
CN117003890B (zh) * 2023-08-09 2024-06-04 成都新诺明生物科技有限公司 一种含有P2和两个Fc的gE融合蛋白及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395278B1 (en) * 1997-02-25 2002-05-28 Corixa Corporation Prostate specific fusion protein compositions
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
JP2002520054A (ja) * 1998-07-14 2002-07-09 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
AU2027400A (en) * 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
JP2004537252A (ja) * 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CN1436234A (zh) * 2000-01-14 2003-08-13 科里克萨有限公司 用于前列腺癌治疗和诊断的组合物及方法
EP1311673A2 (en) * 2000-03-27 2003-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer

Also Published As

Publication number Publication date
BR0311732A (pt) 2005-03-01
NO20045148L (no) 2005-03-01
CO5631450A2 (es) 2006-04-28
PL374534A1 (en) 2005-10-31
CN1675237A (zh) 2005-09-28
MY139557A (en) 2009-10-30
DE60313163D1 (de) 2007-05-24
DE60313163T2 (de) 2008-01-03
CN100360558C (zh) 2008-01-09
EP1511768B1 (en) 2007-04-11
TW200400970A (en) 2004-01-16
CA2487831A1 (en) 2003-12-18
EP1511768A1 (en) 2005-03-09
PT1511768E (pt) 2007-07-16
ES2285174T3 (es) 2007-11-16
KR20050010040A (ko) 2005-01-26
JP2006512047A (ja) 2006-04-13
AR040178A1 (es) 2005-03-16
IS7547A (is) 2004-11-23
DK1511768T3 (da) 2007-08-20
WO2003104272A1 (en) 2003-12-18
ATE359295T1 (de) 2007-05-15
RU2004135541A (ru) 2005-10-10
US20060147477A1 (en) 2006-07-06
NZ537125A (en) 2006-08-31
HK1074846A1 (en) 2005-11-25
AU2003246411A1 (en) 2003-12-22
MXPA04012443A (es) 2005-04-19
UY27840A1 (es) 2003-12-31
IL165372A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ATE144143T1 (de) Künstlicher impfstoff gegen aids-virus
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
ATE267211T1 (de) Impfstoff gegen hpv
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
EP2360176A3 (en) Hybrid and tandem expression of neisserial derived proteins
PE20071055A1 (es) Anticuerpos anti mn
PE20050712A1 (es) Anticuerpos rg1
DE60037450D1 (de) Funf-helix protein
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
DE60032486D1 (de) Prion protein peptide und deren verwendung
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
ES2102347T3 (es) Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
ATE238065T1 (de) Peptide zur verwendung in impfung und anregung von antikörperbildung gegen menschliches immunschwäche virus
PE20030473A1 (es) Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
DK1447414T3 (da) Antagonistpeptider af carcinoembronisk antigen (CEA)
ITRM920350A1 (it) Epitopi immunologicamente omologhi di hla e proteine del virus hiv.
ATE177843T1 (de) Peptomere mit erhöhter immunogenizität
TR200200802T2 (tr) Aşı
DE69941051D1 (de) Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier
ATE306668T1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed